Compliance with follow-up and the informative value of diagnostic whole-body scan patients with differentiated thyroid carcinoma given recombinant human TSH

European Journal of Endocrinology

Volumn 150, Issue 3, 2004, Pages 285-290

  Cohen, Ohad ^a   Dabhi, Sari ^a   Karasik, Avraham ^a   Zwas, S Zila ^a  

^a SHEBA MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 131; RADIOACTIVE IODINE; RECOMBINANT THYROTROPIN; THYROGLOBULIN; THYROID HORMONE;

ADOLESCENT; ADULT; ARTICLE; CANCER RADIOTHERAPY; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; HEADACHE; HUMAN; IMMUNOASSAY; INTERVIEW; MALE; MEDICAL RECORD; PATIENT COMPLIANCE; PATIENT MONITORING; PATIENT REFERRAL; PRIORITY JOURNAL; QUESTIONNAIRE; RADIOGRAPHY; THYROGLOBULIN BLOOD LEVEL; THYROID CARCINOMA; THYROIDECTOMY; TUMOR DIFFERENTIATION; WHOLE BODY SCINTISCANNING;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; FEMALE; FOLLOW-UP STUDIES; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PREDICTIVE VALUE OF TESTS; QUESTIONNAIRES; RECOMBINANT PROTEINS; SUBSTANCE WITHDRAWAL SYNDROME; THYROGLOBULIN; THYROID NEOPLASMS; THYROTROPIN; WHOLE-BODY COUNTING;

EID: 1842526960     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1500285     Document Type: Article

References (15)

1. Cobin R & Gharib H. AACE/AAES medical/surgical guidelines for clinical practice: Management of thyroid carcinoma. Endocrine Practice 2001 7 202-220.
2. Mazzaferri EL. NCCN thyroid carcinoma practice guidelines, NCCN proceedings. Oncology 1999 13 391-442.
3. Haugen BR, Pacini F, Reiners C, Schlumberger M, Ladenson PW, Sherman SI et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. Journal of Clinical Endocrinology and Metabolism 1999 84 3877-3885.
4. Reiners C, Luster M & Lassmann M. Clinical experience with recombinant human thyroid-stimulating hormone (rhTSH): Whole-body scanning with iodine-131. Journal of Endocrinological Investigation 1999 22 (Suppl) 17-24.
5. Schlumberger MJ, Incerti C, Pacini F & Reiners C. The role of recombinant thyroid-stimulating hormone (rhTSH) in the detection and management of well-differentiated thyroid carcinoma: A round table discussion. Journal of Endocrinological Investigation 1999 22 (Suppl) 35-41.
6. Schlumberger MJ. Medical progress: Papillary and follicular thyroid carcinoma. New England Journal of Medicine 1998 338 297-306.
7. Mazzaferri EL & Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. American Journal of Medicine 1994 97 418-428.
8. Cailleux AF, Baudin E, Travagli JP, Ricard M & Schlumberger M. Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer? Journal of Clinical Endocrinology and Metabolism 2000 85 175-178.
9. Mazzaferri EL & Kloos RT. Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation? Journal of Clinical Endocrinology and Metabolism 2002 87 1490-1498.
10. Pacini F, Capezzone M, Elisei R, Ceccarelli C, Taddei D & Pinchera A. Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. Journal of Clinical Endocrinology and Metabolism 2002 87 1499-1501.
11. Wartofsky L. Management of low risk well-differentiated thyroid cancer based only upon thyroglobulin measurement after recombinant human thyrotropin. Thyroid 2002 12 583-590.
12. Haugen BR, Ridgway EC, McLaughlin BA & McDermott MT. Clinical comparison of whole-body radioiodine scan and serum thyroglobulin after stimulation with recombinant human thyrotropin. Thyroid 2002 12 37-43.
13. Robbins RJ, Chon JT, Fleisher M, Larson SM & Tuttle RM. Is the serum thyroglobulin response to recombinant human thyrotropin sufficient, by itself, to monitor for residual thyroid carcinoma? Journal of Clinical Endocrinology and Metabolism 2002 87 3242-3247.
14. Mazzaferri E. NCCN thyroid carcinoma practice guidelines. Oncology 1999 13 391-442.
15. Ladenson PW, Braverman LE, Mazzaferri EL, Brucker-Davis F, Cooper DS, Garber JR et al. Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. New England Journal of Medicine 1997 337 888-896.